Abcam PLC (NASDAQ:ABCZY) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Tuesday.

According to Zacks, “Abcam PLC distributes antibodies and associated protein research tools. Its product includes primary and secondary antibodies, proteins, peptides, lysates, biochemicals, immunoassays and other kits. Abcam PLC is headquartered in Cambridge, the United Kingdom. “

Abcam PLC (NASDAQ ABCZY) traded down 3.894% during mid-day trading on Tuesday, reaching $13.724. 1,043 shares of the company were exchanged. The stock’s 50-day moving average is $13.59 and its 200-day moving average is $12.14. The company has a market cap of $2.77 billion and a P/E ratio of 52.988. Abcam PLC has a 12 month low of $9.13 and a 12 month high of $14.21.

COPYRIGHT VIOLATION NOTICE: “Abcam PLC (ABCZY) Raised to “Hold” at Zacks Investment Research” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://www.thecerbatgem.com/2017/08/29/abcam-plc-abczy-raised-to-hold-at-zacks-investment-research.html.

Receive News & Stock Ratings for Abcam PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abcam PLC and related stocks with our FREE daily email newsletter.